22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
SymbolNYSEAMERICAN:XXII
CUSIPN/A
Phone+1-716-2701523
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-73.20%
Return on Equity-50.30%
Return on Assets-43.77%
Miscellaneous
EmployeesN/A
Outstanding Shares124,380,000
Market Cap$316.82 million
22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions
What is 22nd Century Group's stock symbol?
22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."
How were 22nd Century Group's earnings last quarter?
22nd Century Group Inc (NYSEAMERICAN:XXII) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $6.92 million for the quarter. 22nd Century Group had a negative net margin of 73.20% and a negative return on equity of 50.30%. View 22nd Century Group's Earnings History.
When is 22nd Century Group's next earnings date?
What price target have analysts set for XXII?
1 brokerages have issued twelve-month price objectives for 22nd Century Group's shares. Their predictions range from $11.50 to $11.50. On average, they expect 22nd Century Group's stock price to reach $11.50 in the next year. This suggests a possible upside of 309.3% from the stock's current price. View Analyst Price Targets for 22nd Century Group.
What is the consensus analysts' recommendation for 22nd Century Group?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for 22nd Century Group.
Are investors shorting 22nd Century Group?
22nd Century Group saw a increase in short interest in August. As of August 31st, there was short interest totalling 17,170,467 shares, an increase of 6.8% from the August 15th total of 16,070,701 shares. Based on an average daily trading volume, of 1,726,494 shares, the short-interest ratio is currently 9.9 days. Currently, 15.8% of the company's stock are short sold. View 22nd Century Group's Current Options Chain.
Who are some of 22nd Century Group's key competitors?
Some companies that are related to 22nd Century Group include Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Unity Biotechnology (UBX), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), Protalix Biotherapeutics (PLX) and Neptune Technologies & Bioressources (NEPT).
Who are 22nd Century Group's key executives?
22nd Century Group's management team includes the folowing people:
- Mr. Henry Sicignano III, Pres, CEO & Director (Age 50)
- Mr. John T. Brodfuehrer, CFO & Treasurer (Age 60)
- Mr. Thomas L. James Esq., VP, Gen. Counsel & Sec. (Age 59)
- James Vail, Director of Communications
- Dr. Paul J. Rushton, VP of Plant Biotechnology (Age 55)
Has 22nd Century Group been receiving favorable news coverage?
Headlines about XXII stock have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. 22nd Century Group earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for 22nd Century Group.
Who are 22nd Century Group's major shareholders?
22nd Century Group's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.93%), Northern Trust Corp (1.02%), Sandler Capital Management (0.41%), Bank of New York Mellon Corp (0.27%), Bank of New York Mellon Corp (0.27%) and Schwab Charles Investment Management Inc. (0.20%). Company insiders that own 22nd Century Group stock include Michael Robert Moynihan and Thomas L James. View Institutional Ownership Trends for 22nd Century Group.
Which major investors are selling 22nd Century Group stock?
XXII stock was sold by a variety of institutional investors in the last quarter, including Sandler Capital Management and Bank of America Corp DE. Company insiders that have sold 22nd Century Group company stock in the last year include Michael Robert Moynihan and Thomas L James. View Insider Buying and Selling for 22nd Century Group.
Which major investors are buying 22nd Century Group stock?
XXII stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., NJ State Employees Deferred Compensation Plan, Rhumbline Advisers and State Board of Administration of Florida Retirement System. View Insider Buying and Selling for 22nd Century Group.
How do I buy shares of 22nd Century Group?
Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is 22nd Century Group's stock price today?
One share of XXII stock can currently be purchased for approximately $2.81.
How big of a company is 22nd Century Group?
22nd Century Group has a market capitalization of $316.82 million.
How can I contact 22nd Century Group?
22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.
MarketBeat Community Rating for 22nd Century Group (NYSEAMERICAN XXII)
MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe XXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
